Speaker Profile
Ph.D., CEO, Numenos
Biography
Vitalay Fomin, Ph.D.,CEO of Numenos AI, is an award-winning data scientist at RocheGenentech specializing in biomarker and reverse translation drug discovery
Talk
CURE AI provides efficacy signal from single arm trials
We developed a novel foundation model that is biologically aware capable of using single arm trials to identify optimal indication, patient population and drug combination and optimizes each asset for maximal clinical trial success
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
